

# Nicolas Chomont

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2273415/publications.pdf>

Version: 2024-02-01

190  
papers

15,722  
citations

19657

61  
h-index

19190

118  
g-index

200  
all docs

200  
docs citations

200  
times ranked

11520  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cellular Activation, Differentiation, and Proliferation Influence the Dynamics of Genetically Intact Proviruses Over Time. <i>Journal of Infectious Diseases</i> , 2022, 225, 1168-1178.	4.0	9
2	Camu Camu effects on microbial translocation and systemic immune activation in ART-treated people living with HIV: protocol of the single-arm non-randomised Camu Camu prebiotic pilot study (CIHR/CTN PT032). <i>BMJ Open</i> , 2022, 12, e053081.	1.9	3
3	The ingenol-based protein kinase C agonist GSK445A is a potent inducer of HIV and SIV RNA transcription. <i>PLoS Pathogens</i> , 2022, 18, e1010245.	4.7	11
4	Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy. <i>Science Translational Medicine</i> , 2022, 14, eabl3836.	12.4	50
5	The HIV-1 proviral landscape reveals that Nef contributes to HIV-1 persistence in effector memory CD4+ T cells. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	52
6	T cell migration potentiates HIV infection by enhancing viral fusion and integration. <i>Cell Reports</i> , 2022, 38, 110406.	6.4	6
7	Impact of Tamoxifen on Vorinostat-Induced Human Immunodeficiency Virus Expression in Women on Antiretroviral Therapy: AIDS Clinical Trials Group A5366, The MOXIE Trial. <i>Clinical Infectious Diseases</i> , 2022, 75, 1389-1396.	5.8	9
8	Persistent HIV transcription and variable antiretroviral drug penetration in lymph nodes during plasma viral suppression. <i>Aids</i> , 2022, 36, 985-990.	2.2	12
9	First-in-human immunopET imaging of HIV-1 infection using 89Zr-labeled VRC01 broadly neutralizing antibody. <i>Nature Communications</i> , 2022, 13, 1219.	12.8	20
10	Combination Immune Checkpoint Blockade Enhances IL-2 and CD107a Production from HIV-Specific T Cells Ex Vivo in People Living with HIV on Antiretroviral Therapy. <i>Journal of Immunology</i> , 2022, 208, 54-62.	0.8	16
11	Willingness of Older Canadians with HIV to Participate in HIV Cure Research Near and After the End of Life: A Mixed-Method Study. <i>AIDS Research and Human Retroviruses</i> , 2022, 38, 670-682.	1.1	5
12	HIV persistence in subsets of CD4+ T cells: 50 shades of reservoirs. <i>Seminars in Immunology</i> , 2021, 51, 101438.	5.6	36
13	Continuous Prophylactic Antiretrovirals/Antiretroviral Therapy Since Birth Reduces Seeding and Persistence of the Viral Reservoir in Children Vertically Infected With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2021, 73, 427-438.	5.8	13
14	Assessing the Suitability of Next-Generation Viral Outgrowth Assays to Measure Human Immunodeficiency Virus 1 Latent Reservoir Size. <i>Journal of Infectious Diseases</i> , 2021, 224, 1209-1218.	4.0	18
15	Intact Human Immunodeficiency Virus (HIV) Reservoir Estimated by the Intact Proviral DNA Assay Correlates With Levels of Total and Integrated DNA in the Blood During Suppressive Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2021, 72, 495-498.	5.8	23
16	Peculiar Phenotypic and Cytotoxic Features of Pulmonary Mucosal CD8 T Cells in People Living with HIV Receiving Long-Term Antiretroviral Therapy. <i>Journal of Immunology</i> , 2021, 206, 641-651.	0.8	5
17	Safety, Immune, and Antiviral Effects of Pegylated Interferon Alpha 2b Administration in Antiretroviral Therapy-Suppressed Individuals: Results of Pilot Clinical Trial. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 433-443.	1.1	9
18	Gag p24 Is a Marker of Human Immunodeficiency Virus Expression in Tissues and Correlates With Immune Response. <i>Journal of Infectious Diseases</i> , 2021, 224, 1593-1598.	4.0	14

#	ARTICLE	IF	CITATIONS
19	Differences in HIV burden in the inflamed and non-inflamed colon from a person living with HIV and ulcerative colitis. <i>Journal of Virus Eradication</i> , 2021, 7, 100033.	0.5	6
20	LILAC pilot study: Effects of metformin on mTOR activation and HIV reservoir persistence during antiretroviral therapy. <i>EBioMedicine</i> , 2021, 65, 103270.	6.1	46
21	Identification of SARS-CoV-2-specific immune alterations in acutely ill patients. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	24
22	Upregulated IL-32 Expression And Reduced Gut Short Chain Fatty Acid Caproic Acid in People Living With HIV With Subclinical Atherosclerosis. <i>Frontiers in Immunology</i> , 2021, 12, 664371.	4.8	25
23	Loss of CD96 Expression as a Marker of HIV-Specific CD8+ T-Cell Differentiation and Dysfunction. <i>Frontiers in Immunology</i> , 2021, 12, 673061.	4.8	5
24	RALDH Activity Induced by Bacterial/Fungal Pathogens in CD16+ Monocyte-Derived Dendritic Cells Boosts HIV Infection and Outgrowth in CD4+ T Cells. <i>Journal of Immunology</i> , 2021, 206, 2638-2651.	0.8	7
25	Long-term effects of early antiretroviral initiation on HIV reservoir markers: a longitudinal analysis of the MERLIN clinical study. <i>Lancet Microbe</i> , The, 2021, 2, e198-e209.	7.3	24
26	In-depth single-cell analysis of translation-competent HIV-1 reservoirs identifies cellular sources of plasma viremia. <i>Nature Communications</i> , 2021, 12, 3727.	12.8	43
27	Brief Report: Subclinical Carotid Artery Atherosclerosis Is Associated With Increased Expression of Peripheral Blood IL-32 Isoforms Among Women Living With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 88, 186-191.	2.1	3
28	Increased homeostatic cytokines and stability of HIV-infected memory CD4 T-cells identify individuals with suboptimal CD4 T-cell recovery on-ART. <i>PLoS Pathogens</i> , 2021, 17, e1009825.	4.7	17
29	Combined single-cell transcriptional, translational, and genomic profiling reveals HIV-1 reservoir diversity. <i>Cell Reports</i> , 2021, 36, 109643.	6.4	34
30	IL-17A reprograms intestinal epithelial cells to facilitate HIV-1 replication and outgrowth in CD4+ T cells. <i>iScience</i> , 2021, 24, 103225.	4.1	3
31	Preferential and persistent impact of acute HIV-1 infection on CD4 <sup>+</sup> iNKT cells in colonic mucosa. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	2
32	Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality. <i>Science Advances</i> , 2021, 7, eabj5629.	10.3	32
33	Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021. <i>Nature Medicine</i> , 2021, 27, 2085-2098.	30.7	146
34	Clinical Correlates of Human Immunodeficiency Virus-1 (HIV-1) DNA and Inducible HIV-1 RNA Reservoirs in Peripheral Blood in Children With Perinatally Acquired HIV-1 Infection With Sustained Virologic Suppression for at Least 5 Years. <i>Clinical Infectious Diseases</i> , 2020, 70, 859-866.	5.8	20
35	Viral Blips After Treatment Initiation During Acute Human Immunodeficiency Virus Infection. <i>Clinical Infectious Diseases</i> , 2020, 70, 2706-2709.	5.8	11
36	High levels of genetically intact HIV in HLA-DR+ memory T cells indicates their value for reservoir studies. <i>Aids</i> , 2020, 34, 659-668.	2.2	32

#	ARTICLE	IF	CITATIONS
37	Human Immunodeficiency Virus (HIV)â€“Infected CCR6+ Rectal CD4+ T Cells and HIV Persistence On Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2020, 221, 744-755.	4.0	39
38	A randomized trial of vorinostat with treatment interruption after initiating antiretroviral therapy during acute HIV-1 infection. <i>Journal of Virus Eradication</i> , 2020, 6, 100004.	0.5	23
39	Highlights of the 9th edition of the Conference on HIV Persistence During Therapy, 10â€“13 December 2019, Miami, USA. <i>Journal of Virus Eradication</i> , 2020, 6, 85-95.	0.5	0
40	Fingolimod inhibits multiple stages of the HIV-1 life cycle. <i>PLoS Pathogens</i> , 2020, 16, e1008679.	4.7	8
41	Single-cell TCR sequencing reveals phenotypically diverse clonally expanded cells harboring inducible HIV proviruses during ART. <i>Nature Communications</i> , 2020, 11, 4089.	12.8	77
42	Potential for Virus Endogenization in Humans through Testicular Germ Cell Infection: the Case of HIV. <i>Journal of Virology</i> , 2020, 94, .	3.4	15
43	HIV Infection and Persistence in Pulmonary Mucosal Double Negative T Cells In Vivo. <i>Journal of Virology</i> , 2020, 94, .	3.4	12
44	Recommendations for measuring HIV reservoir size in cure-directed clinical trials. <i>Nature Medicine</i> , 2020, 26, 1339-1350.	30.7	96
45	Genetic Diversity, Compartmentalization, and Age of HIV Proviruses Persisting in CD4 <sup>+</sup> T Cell Subsets during Long-Term Combination Antiretroviral Therapy. <i>Journal of Virology</i> , 2020, 94, .	3.4	21
46	â€“Rinse and Replaceâ€™: Boosting T Cell Turnover To Reduce HIV-1 Reservoirs. <i>Trends in Immunology</i> , 2020, 41, 466-480.	6.8	26
47	Virologic and Immunologic Features of Simian Immunodeficiency Virus Control Post-ART Interruption in Rhesus Macaques. <i>Journal of Virology</i> , 2020, 94, .	3.4	13
48	Improving HIV Outgrowth by Optimizing Cell-Culture Conditions and Supplementing With all-trans Retinoic Acid. <i>Frontiers in Microbiology</i> , 2020, 11, 902.	3.5	15
49	Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption. <i>Nature Medicine</i> , 2020, 26, 498-501.	30.7	43
50	Abundant HIV-infected cells in blood and tissues are rapidly cleared upon ART initiation during acute HIV infection. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	69
51	Combination Immune Checkpoint Blockade to Reverse HIV Latency. <i>Journal of Immunology</i> , 2020, 204, 1242-1254.	0.8	38
52	Preferential Infection of $\text{IL}4^{\text{hi}}\text{CD}27^{\text{+}}$ Memory CD4+ T Cells During Early Acute Human Immunodeficiency Virus Type 1 Infection. <i>Clinical Infectious Diseases</i> , 2020, 71, e735-e743.	5.8	14
53	The Biology of the HIV-1 Latent Reservoir and Implications for Cure Strategies. <i>Cell Host and Microbe</i> , 2020, 27, 519-530.	11.0	173
54	Persistent expansion and Th1-like skewing of HIV-specific circulating T follicular helper cells during antiretroviral therapy. <i>EBioMedicine</i> , 2020, 54, 102727.	6.1	42

#	ARTICLE	IF	CITATIONS
55	Impact of Antiretroviral Therapy Duration on HIV-1 Infection of T Cells within Anatomic Sites. <i>Journal of Virology</i> , 2020, 94, .	3.4	20
56	HIV enters deep sleep in people who naturally control the virus. <i>Nature</i> , 2020, 585, 190-191.	27.8	8
57	Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound. <i>Journal of Clinical Investigation</i> , 2020, 130, 3299-3304.	8.2	24
58	The multifaceted nature of HIV latency. <i>Journal of Clinical Investigation</i> , 2020, 130, 3381-3390.	8.2	49
59	Pharmacological Inhibition of PPAR $\alpha$ Boosts HIV Reactivation and Th17 Effector Functions, while Preventing Progeny Virion Release and <i>de novo</i> Infection. <i>Pathogens and Immunity</i> , 2020, 5, 177.	3.1	12
60	Highlights of the 9th edition of the Conference on HIV Persistence During Therapy, 10-13 December 2019, Miami, USA. <i>Journal of Virus Eradication</i> , 2020, 6, 85-95.	0.5	0
61	Fingolimod inhibits multiple stages of the HIV-1 life cycle. , 2020, 16, e1008679.		0
62	Fingolimod inhibits multiple stages of the HIV-1 life cycle. , 2020, 16, e1008679.		0
63	Fingolimod inhibits multiple stages of the HIV-1 life cycle. , 2020, 16, e1008679.		0
64	Fingolimod inhibits multiple stages of the HIV-1 life cycle. , 2020, 16, e1008679.		0
65	Fingolimod inhibits multiple stages of the HIV-1 life cycle. , 2020, 16, e1008679.		0
66	Fingolimod inhibits multiple stages of the HIV-1 life cycle. , 2020, 16, e1008679.		0
67	Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4 <sup>+</sup> T-cell Immunophenotyping and HIV Reservoir Assessment. <i>Journal of Visualized Experiments</i> , 2019, , .	0.3	8
68	Memory CD4 + T-Cells Expressing HLA-DR Contribute to HIV Persistence During Prolonged Antiretroviral Therapy. <i>Frontiers in Microbiology</i> , 2019, 10, 2214.	3.5	38
69	Infrequent HIV Infection of Circulating Monocytes during Antiretroviral Therapy. <i>Journal of Virology</i> , 2019, 94, .	3.4	23
70	Oral cannabinoids in people living with HIV on effective antiretroviral therapy: CTN PT028â€”study protocol for a pilot randomised trial to assess safety, tolerability and effect on immune activation. <i>BMJ Open</i> , 2019, 9, e024793.	1.9	31
71	HIV Diversity and Genetic Compartmentalization in Blood and Testes during Suppressive Antiretroviral Therapy. <i>Journal of Virology</i> , 2019, 93, .	3.4	35
72	Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial. <i>Lancet HIV</i> , the, 2019, 6, e297-e306.	4.7	73

#	ARTICLE	IF	CITATIONS
73	Effect of metformin on the size of the HIV reservoir in non-diabetic ART-treated individuals: single-arm non-randomised Lilac pilot study protocol. <i>BMJ Open</i> , 2019, 9, e028444.	1.9	39
74	Single-cell characterization and quantification of translation-competent viral reservoirs in treated and untreated HIV infection. <i>PLoS Pathogens</i> , 2019, 15, e1007619.	4.7	177
75	Modeling HIV-1 Latency Using Primary CD4 <sup>+</sup> T Cells from Virally Suppressed HIV-1-Infected Individuals on Antiretroviral Therapy. <i>Journal of Virology</i> , 2019, 93, .	3.4	9
76	PD-1 blockade potentiates HIV latency reversal ex vivo in CD4 <sup>+</sup> T cells from ART-suppressed individuals. <i>Nature Communications</i> , 2019, 10, 814.	12.8	149
77	Differentiation into an Effector Memory Phenotype Potentiates HIV-1 Latency Reversal in CD4 <sup>+</sup> T Cells. <i>Journal of Virology</i> , 2019, 93, .	3.4	72
78	Latency-Reversing Agents Induce Differential Responses in Distinct Memory CD4 <sup>+</sup> T Cell Subsets in Individuals on Antiretroviral Therapy. <i>Cell Reports</i> , 2019, 29, 2783-2795.e5.	6.4	51
79	Upregulation of IL-32 Isoforms in Virologically Suppressed HIV-Infected Individuals: Potential Role in Persistent Inflammation and Transcription From Stable HIV-1 Reservoirs. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, 503-513.	2.1	21
80	Human Immunodeficiency Virus (HIV)-Antibody Repertoire Estimates Reservoir Size and Time of Antiretroviral Therapy Initiation in Virally Suppressed Perinatally HIV-Infected Children. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2019, 8, 433-438.	1.3	29
81	Cellular Metabolism Is a Major Determinant of HIV-1 Reservoir Seeding in CD4 <sup>+</sup> T Cells and Offers an Opportunity to Tackle Infection. <i>Cell Metabolism</i> , 2019, 29, 611-626.e5.	16.2	124
82	Sex-Based Differences in Human Immunodeficiency Virus Type 1 Reservoir Activity and Residual Immune Activation. <i>Journal of Infectious Diseases</i> , 2019, 219, 1084-1094.	4.0	73
83	Acute Retroviral Syndrome Is Associated With High Viral Burden, CD4 Depletion, and Immune Activation in Systemic and Tissue Compartments. <i>Clinical Infectious Diseases</i> , 2018, 66, 1540-1549.	5.8	32
84	Wake me up before you go. <i>Aids</i> , 2018, 32, 293-298.	2.2	9
85	Highlights from the 8th International Workshop on HIV Persistence during Therapy, 12–15 December 2017, Miami, FL, USA. <i>Journal of Virus Eradication</i> , 2018, 4, 132-142.	0.5	0
86	A-108 The Contribution of memory CD4 <sup>+</sup> T cell subset phenotype to latency reversal efficiency. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 35-35.	2.1	0
87	Anti-IL-4 <sup>27</sup> therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1-infected individuals. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	65
88	HIV persistence in mucosal CD4 <sup>+</sup> T cells within the lungs of adults receiving long-term suppressive antiretroviral therapy. <i>Aids</i> , 2018, 32, 2279-2289.	2.2	44
89	Estrogen receptor-1 is a key regulator of HIV-1 latency that imparts gender-specific restrictions on the latent reservoir. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E7795-E7804.	7.1	121
90	Inducible HIV RNA transcription assays to measure HIV persistence: pros and cons of a compromise. <i>Retrovirology</i> , 2018, 15, 9.	2.0	25

#	ARTICLE	IF	CITATIONS
91	Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency. <i>Aids</i> , 2018, 32, 1491-1497.	2.2	136
92	Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection. <i>Nature Medicine</i> , 2018, 24, 923-926.	30.7	263
93	Distinct biomarker signatures in HIV acute infection associate with viral dynamics and reservoir size. <i>JCI Insight</i> , 2018, 3, .	5.0	32
94	Central Memory CD4 T Cells. , 2018, , 268-275.		0
95	Highlights from the 8 International Workshop on HIV Persistence during Therapy, 12-15 December 2017, Miami, FL, USA. <i>Journal of Virus Eradication</i> , 2018, 4, 132-142.	0.5	1
96	Delayed differentiation of potent effector CD8 <sup>+</sup> T cells reducing viremia and reservoir seeding in acute HIV infection. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	95
97	Human Immunodeficiency Virus Persistence and T-Cell Activation in Blood, Rectal, and Lymph Node Tissue in Human Immunodeficiency Virus-Infected Individuals Receiving Suppressive Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2017, 215, 911-919.	4.0	95
98	Association of Arterial and Lymph Node Inflammation With Distinct Inflammatory Pathways in Human Immunodeficiency Virus Infection. <i>JAMA Cardiology</i> , 2017, 2, 163.	6.1	50
99	Identification of Genetically Intact HIV-1 Proviruses in Specific CD4 + T Cells from Effectively Treated Participants. <i>Cell Reports</i> , 2017, 21, 813-822.	6.4	304
100	Multiparametric characterization of rare HIV-infected cells using an RNA-flow FISH technique. <i>Nature Protocols</i> , 2017, 12, 2029-2049.	12.0	55
101	HIV persists in CCR6+CD4+ T cells from colon and blood during antiretroviral therapy. <i>Aids</i> , 2017, 31, 35-48.	2.2	122
102	Persistent, Albeit Reduced, Chronic Inflammation in Persons Starting Antiretroviral Therapy in Acute HIV Infection. <i>Clinical Infectious Diseases</i> , 2017, 64, 124-131.	5.8	200
103	The evaluation of risk-benefit ratio for gut tissue sampling in HIV cure research. <i>Journal of Virus Eradication</i> , 2017, 3, 212-217.	0.5	12
104	HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study. <i>PLoS Medicine</i> , 2017, 14, e1002417.	8.4	186
105	Extensive virologic and immunologic characterization in an HIV-infected individual following allogeneic stem cell transplant and analytic cessation of antiretroviral therapy: A case study. <i>PLoS Medicine</i> , 2017, 14, e1002461.	8.4	50
106	The evaluation of risk-benefit ratio for gut tissue sampling in HIV cure research. <i>Journal of Virus Eradication</i> , 2017, 3, 212-217.	0.5	11
107	Virological and immunological characteristics of HIV-infected individuals at the earliest stage of infection. <i>Journal of Virus Eradication</i> , 2016, 2, 43-48.	0.5	73
108	Initiation of antiretroviral therapy before detection of colonic infiltration by HIV reduces viral reservoirs, inflammation and immune activation. <i>Journal of the International AIDS Society</i> , 2016, 19, 21163.	3.0	37

#	ARTICLE	IF	CITATIONS
109	DNA/MVA Vaccination of HIV-1 Infected Participants with Viral Suppression on Antiretroviral Therapy, followed by Treatment Interruption: Elicitation of Immune Responses without Control of Re-Emergent Virus. PLoS ONE, 2016, 11, e0163164.	2.5	26
110	Loss of Function of Intestinal IL-17 and IL-22 Producing Cells Contributes to Inflammation and Viral Persistence in SIV-Infected Rhesus Macaques. PLoS Pathogens, 2016, 12, e1005412.	4.7	53
111	Residual inflammation and viral reservoirs. Current Opinion in HIV and AIDS, 2016, 11, 234-241.	3.8	107
112	International AIDS Society global scientific strategy: towards an HIV cure 2016. Nature Medicine, 2016, 22, 839-850.	30.7	395
113	Persistence of integrated HIV DNA in CXCR3 <sup>+</sup> CCR6 <sup>+</sup> memory CD4 <sup>+</sup> T cells in HIV-infected individuals on antiretroviral therapy. Aids, 2016, 30, 1511-1520.	2.2	68
114	Antiretroviral drug transporters and metabolic enzymes in human testicular tissue: potential contribution to HIV-1 sanctuary site. Journal of Antimicrobial Chemotherapy, 2016, 71, 1954-1965.	3.0	46
115	HIV DNA Set Point is Rapidly Established in Acute HIV Infection and Dramatically Reduced by Early ART. EBioMedicine, 2016, 11, 68-72.	6.1	193
116	Single-Cell Characterization of Viral Translation-Competent Reservoirs in HIV-Infected Individuals. Cell Host and Microbe, 2016, 20, 368-380.	11.0	170
117	New insights into the heterogeneity of Th17 subsets contributing to HIV-1 persistence during antiretroviral therapy. Retrovirology, 2016, 13, 59.	2.0	90
118	Strategies for targeting residual HIV infection. Current Opinion in HIV and AIDS, 2016, 11, 359-361.	3.8	2
119	Immune tolerance properties of the testicular tissue as a viral sanctuary site in ART-treated HIV-infected adults. Aids, 2016, 30, 2777-2786.	2.2	45
120	Impaired gut junctional complexes feature late-treated individuals with suboptimal CD4 <sup>+</sup> T-cell recovery upon virologically suppressive combination antiretroviral therapy. Aids, 2016, 30, 991-1003.	2.2	55
121	Anti-HIV Antibody Responses and the HIV Reservoir Size during Antiretroviral Therapy. PLoS ONE, 2016, 11, e0160192.	2.5	26
122	CD4 <sup>+</sup> T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART. PLoS Pathogens, 2016, 12, e1005761.	4.7	350
123	Virological and immunological characteristics of HIV-infected individuals at the earliest stage of infection. Journal of Virus Eradication, 2016, 2, 43-48.	0.5	45
124	A Novel Assay to Measure the Magnitude of the Inducible Viral Reservoir in HIV-infected Individuals. EBioMedicine, 2015, 2, 874-883.	6.1	242
125	Identification of novel HIV-1 dependency factors in primary CCR4 <sup>+</sup> CCR6 <sup>+</sup> Th17 cells via a genome-wide transcriptional approach. Retrovirology, 2015, 12, 102.	2.0	54
126	The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo. PLoS Pathogens, 2015, 11, e1005142.	4.7	445



#	ARTICLE	IF	CITATIONS
127	Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification. <i>Journal of Virus Eradication</i> , 2015, 1, 116-122.	0.5	50
128	HIV persistence in the setting of antiretroviral therapy: when, where and how does HIV hide?. <i>Journal of Virus Eradication</i> , 2015, 1, 59-66.	0.5	71
129	Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. <i>Science Translational Medicine</i> , 2015, 7, 319ra206.	12.4	390
130	Nef promotes evasion of human immunodeficiency virus type 1-infected cells from the CTLA-4-mediated inhibition of T-cell activation. <i>Journal of General Virology</i> , 2015, 96, 1463-1477.	2.9	17
131	The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency. <i>MBio</i> , 2015, 6, e00465.	4.1	188
132	HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses. <i>Journal of Virology</i> , 2015, 89, 9189-9199.	3.4	33
133	How does the timing of antiretroviral therapy initiation in acute infection affect HIV reservoirs?. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 18-28.	3.8	99
134	Interleukin-21 combined with ART reduces inflammation and viral reservoir in SIV-infected macaques. <i>Journal of Clinical Investigation</i> , 2015, 125, 4497-4513.	8.2	104
135	HIV persistence in the setting of antiretroviral therapy: when, where and how does HIV hide?. <i>Journal of Virus Eradication</i> , 2015, 1, 59-66.	0.5	51
136	Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification. <i>Journal of Virus Eradication</i> , 2015, 1, 116-122.	0.5	36
137	Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy. <i>PLoS Pathogens</i> , 2014, 10, e1004473.	4.7	437
138	Reduced markers of HIV persistence and restricted HIV-specific immune responses after early antiretroviral therapy in children. <i>Aids</i> , 2014, 28, 1015-1020.	2.2	108
139	Central Memory CD4 T Cells. , 2014, , 1-8.		0
140	HIV Antibody Characterization as a Method to Quantify Reservoir Size During Curative Interventions. <i>Journal of Infectious Diseases</i> , 2014, 209, 1613-1617.	4.0	48
141	Cross-Clade Ultrasensitive PCR-Based Assays To Measure HIV Persistence in Large-Cohort Studies. <i>Journal of Virology</i> , 2014, 88, 12385-12396.	3.4	198
142	CD4+ and CD8+ T Cell Activation Are Associated with HIV DNA in Resting CD4+ T Cells. <i>PLoS ONE</i> , 2014, 9, e110731.	2.5	88
143	A novel acute HIV infection staging system based on 4th generation immunoassay. <i>Retrovirology</i> , 2013, 10, 56.	2.0	93
144	The immunological synapse: the gateway to the <sc>HIV</sc> reservoir. <i>Immunological Reviews</i> , 2013, 254, 305-325.	6.0	38

#	ARTICLE	IF	CITATIONS
145	Immune activation and HIV persistence: implications for curative approaches to HIV infection. <i>Immunological Reviews</i> , 2013, 254, 326-342.	6.0	334
146	Programmed Death-1 Is a Marker for Abnormal Distribution of Naive/Memory T Cell Subsets in HIV-1 Infection. <i>Journal of Immunology</i> , 2013, 191, 2194-2204.	0.8	81
147	High Levels of CD2 Expression Identify HIV-1 Latently Infected Resting Memory CD4 <sup>+</sup> T Cells in Virally Suppressed Subjects. <i>Journal of Virology</i> , 2013, 87, 9148-9158.	3.4	91
148	A candidate anti-HIV reservoir compound, auranofin, exerts a selective anti-memory effect by exploiting the baseline oxidative status of lymphocytes. <i>Cell Death and Disease</i> , 2013, 4, e944-e944.	6.3	49
149	Interleukin-7 promotes HIV persistence during antiretroviral therapy. <i>Blood</i> , 2013, 121, 4321-4329.	1.4	199
150	Down-Regulation of CTLA-4 by HIV-1 Nef Protein. <i>PLoS ONE</i> , 2013, 8, e54295.	2.5	20
151	Design and Implementation of a Randomized Crossover Study of Valproic Acid and Antiretroviral Therapy to Reduce the HIV Reservoir. <i>HIV Clinical Trials</i> , 2012, 13, 301-307.	2.0	11
152	Profound metabolic, functional, and cytolytic differences characterize HIV-specific CD8 T cells in primary and chronic HIV infection. <i>Blood</i> , 2012, 120, 3466-3477.	1.4	70
153	An Analog of the Natural Steroidal Alkaloid Cortistatin A Potently Suppresses Tat-Dependent HIV Transcription. <i>Cell Host and Microbe</i> , 2012, 12, 97-108.	11.0	159
154	CD4 T cell nadir independently predicts the magnitude of the HIV reservoir after prolonged suppressive antiretroviral therapy. <i>Journal of Clinical Virology</i> , 2012, 53, 29-32.	3.1	89
155	Conference highlights of the 5th international workshop on HIV persistence during therapy, 6-9 December 2011, St. Maartin, West Indies. <i>AIDS Research and Therapy</i> , 2012, 9, 7.	1.7	2
156	The role of cytokines in the establishment, persistence and eradication of the HIV reservoir. <i>Cytokine and Growth Factor Reviews</i> , 2012, 23, 143-149.	7.2	54
157	The Colocalization Potential of HIV-Specific CD8 <sup>+</sup> and CD4 <sup>+</sup> T-Cells is Mediated by Integrin $\beta$ 7 but Not CCR6 and Regulated by Retinoic Acid. <i>PLoS ONE</i> , 2012, 7, e32964.	2.5	17
158	Towards an HIV cure: a global scientific strategy. <i>Nature Reviews Immunology</i> , 2012, 12, 607-614.	22.7	485
159	Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV reservoirs: results from a multicentre randomized clinical study. <i>HIV Medicine</i> , 2012, 13, 291-296.	2.2	99
160	Potent suppression of HIV viral replication by a novel inhibitor of Tat. <i>Retrovirology</i> , 2012, 9, .	2.0	1
161	Impact of Multi-Targeted Antiretroviral Treatment on Gut T Cell Depletion and HIV Reservoir Seeding during Acute HIV Infection. <i>PLoS ONE</i> , 2012, 7, e33948.	2.5	276
162	Loss of memory B cells during chronic HIV infection is driven by Foxo3a- and TRAIL-mediated apoptosis. <i>Journal of Clinical Investigation</i> , 2012, 122, 2704-2704.	8.2	0

#	ARTICLE	IF	CITATIONS
163	Finding a cure for HIV: will it ever be achievable?. Journal of the International AIDS Society, 2011, 14, 4-4.	3.0	39
164	Gold drug auranofin restricts the viral reservoir in the monkey AIDS model and induces containment of viral load following ART suspension. Aids, 2011, 25, 1347-1356.	2.2	74
165	Maintenance of CD4+ T-cell memory and HIV persistence: keeping memory, keeping HIV. Current Opinion in HIV and AIDS, 2011, 6, 30-36.	3.8	74
166	Loss of memory B cells during chronic HIV infection is driven by Foxo3a- and TRAIL-mediated apoptosis. Journal of Clinical Investigation, 2011, 121, 3877-3888.	8.2	95
167	Peripheral Blood CCR4+CCR6+ and CXCR3+CCR6+ CD4+ T Cells Are Highly Permissive to HIV-1 Infection. Journal of Immunology, 2010, 184, 1604-1616.	0.8	279
168	HIV Persistence and the Prospect of Long-Term Drug-Free Remissions for HIV-Infected Individuals. Science, 2010, 329, 174-180.	12.6	274
169	HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nature Medicine, 2009, 15, 893-900.	30.7	1,519
170	P16-54 LB. Blood CCR6+ Th17 and Th1Th17 but not CCR6neg Th1 cells are targets for HIV replication and their frequency is diminished in HIV-infected subjects. Retrovirology, 2009, 6, P407.	2.0	0
171	Transcription factor FOXO3a controls the persistence of memory CD4+ T cells during HIV infection. Nature Medicine, 2008, 14, 266-274.	30.7	139
172	Neutralizing monoclonal antibodies to human immunodeficiency virus type 1 do not inhibit viral transcytosis through mucosal epithelial cells. Virology, 2008, 370, 246-254.	2.4	37
173	Lymph node architecture collapse and consequent modulation of FOXO3a pathway on memory T- and B-cells during HIV infection. Seminars in Immunology, 2008, 20, 196-203.	5.6	29
174	Oponization of HIV with Complement Enhances Infection of Dendritic Cells and Viral Transfer to CD4 T Cells in a CR3 and DC-SIGN-Dependent Manner. Journal of Immunology, 2007, 178, 1086-1095.	0.8	57
175	Genetic and Phenotypic Features of Blood and Genital Viral Populations of Clinically Asymptomatic and Antiretroviral-Treatment-Naive Clade A Human Immunodeficiency Virus Type 1-Infected Women. Journal of Clinical Microbiology, 2007, 45, 1838-1842.	3.9	23
176	Drug resistance mutations and the cellular immune response: a valuable synergy for the development of novel immune therapies. Current Opinion in HIV and AIDS, 2007, 2, 116-122.	3.8	2
177	Programmed death 1: a critical regulator of T-cell function and a strong target for immunotherapies for chronic viral infections. Current Opinion in HIV and AIDS, 2007, 2, 219-227.	3.8	17
178	Early archives of genetically-restricted proviral DNA in the female genital tract after heterosexual transmission of HIV-1. Aids, 2007, 21, 153-162.	2.2	26
179	Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nature Medicine, 2006, 12, 1198-1202.	30.7	1,376
180	Enterovirus RNA shedding in the genital tract of childbearing-aged women living in Central Africa. Journal of Medical Virology, 2006, 78, 591-597.	5.0	2

#	ARTICLE	IF	CITATIONS
181	Independent Levels of Cell-Free and Cell-Associated Human Immunodeficiency Virus-1 in Genital Tract Secretions of Clinically Asymptomatic, Treatment-Naive African Women. <i>Journal of Infectious Diseases</i> , 2003, 188, 549-554.	4.0	18
182	Comparison of Washing and Swabbing Procedures for Collecting Genital Fluids To Assess Shedding of Human Immunodeficiency Virus Type 1 (HIV-1) RNA in Asymptomatic HIV-1-Infected Women. <i>Journal of Clinical Microbiology</i> , 2003, 41, 449-452.	3.9	9
183	Oponization of HIV-1 by Semen Complement Enhances Infection of Human Epithelial Cells. <i>Journal of Immunology</i> , 2002, 169, 3301-3306.	0.8	89
184	Binding of LFA-1 (CD11a) to Intercellular Adhesion Molecule 3 (ICAM-3; CD50) and ICAM-2 (CD102) Triggers Transmigration of Human Immunodeficiency Virus Type 1-Infected Monocytes through Mucosal Epithelial Cells. <i>Journal of Virology</i> , 2002, 76, 32-40.	3.4	30
185	Compartmentalization of HIV-1 between Breast Milk and Blood of HIV-Infected Mothers. <i>Virology</i> , 2002, 300, 109-117.	2.4	71
186	Active and Selective Transcytosis of Cell-Free Human Immunodeficiency Virus through a Tight Polarized Monolayer of Human Endometrial Cells. <i>Journal of Virology</i> , 2001, 75, 5370-5374.	3.4	75
187	Cervicovaginal Secretory Antibodies to Human Immunodeficiency Virus Type 1 (HIV-1) that Block Viral Transcytosis through Tight Epithelial Barriers in Highly Exposed HIV-1-Seronegative African Women. <i>Journal of Infectious Diseases</i> , 2001, 184, 1412-1422.	4.0	106
188	Opposite Effects of IL-10 on the Ability of Dendritic Cells and Macrophages to Replicate Primary CXCR4-Dependent HIV-1 Strains. <i>Journal of Immunology</i> , 2001, 166, 4244-4253.	0.8	44
189	Detection of Y Chromosome DNA as Evidence of Semen in Cervicovaginal Secretions of Sexually Active Women. <i>Vaccine Journal</i> , 2001, 8, 955-958.	2.6	35
190	Polymerase chain reaction for Y chromosome to detect semen in cervicovaginal fluid: a prerequisite to assess HIV-specific vaginal immunity and HIV genital shedding. <i>Aids</i> , 2001, 15, 801-802.	2.2	17